Literature DB >> 19360752

Overexpression of Akt/PKB modulates N-myristoyltransferase activity in cancer cells.

Anuraag Shrivastav1, Shailly Varma, Arnie Senger, Ramji L Khandelwal, Svein Carlsen, Rajendra K Sharma.   

Abstract

N-myristoyltransferase (NMT) catalyses the myristoylation reaction. Since NMT activity is elevated in various cancers and activated Akt/PKB leads to cell survival, we were interested in studying if activation of Akt/PKB has any effect on NMT. Overexpression of constitutively active Akt/PKB in HepG2 cells (HepG2-CA-Akt/PKB) led to an approximately 50% reduction of NMT compared with parental HepG2 cells. Reduced NMT activity in HepG2-CA-Akt/PKB was found to be due to the NMT1 phosphorylation. We determined NMT activity in various human breast cancer cell lines with differing metastatic potentials and pseudo-normal breast cells (HBL-100). Tumourigenic or metastatic breast cancer cell lines such as MDA-MB-231, MDA-MB-435, and Hs 578T displayed reduced NMT activity. Western blot analysis revealed that NMT1 is phosphorylated in these breast cancer cells. Furthermore, patients' breast cancer tissue array revealed strong positivity and high intensity for NMT in malignant breast tissues compared with normal breast cells. A gradation in the NMT staining was observed for grade I, II, and III infiltrating ductal carcinoma breast tissues. These studies demonstrate that overexpression of Akt/PKB results in NMT1 phosphorylation and that NMT1 is phosphorylated in breast cancer cells. Immunohistochemical analysis suggests that NMT may prove to be an added diagnostic biomarker for breast cancer. 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360752     DOI: 10.1002/path.2550

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  NMT1 (N-myristoyltransferase 1).

Authors:  Ponniah Selvakumar; Sujeet Kumar; Jonathan R Dimmock; Rajendra K Sharma
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2011-01-07

2.  RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells.

Authors:  Lena Hölzen; Jan Mitschke; Claudia Schönichen; Maria Elena Hess; Sophia Ehrenfeld; Melanie Boerries; Cornelius Miething; Tilman Brummer; Thomas Reinheckel
Journal:  Theranostics       Date:  2022-05-16       Impact factor: 11.600

3.  Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.

Authors:  Begoña Díaz; Katherine T Ostapoff; Jason E Toombs; Jason Lo; Michael Y Bonner; Adam Curatolo; Volkan Adsay; Rolf A Brekken; Jack L Arbiser
Journal:  Oncotarget       Date:  2016-08-09

4.  In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases.

Authors:  Ranjit Chauhan; David Datzkiw; Shailly Varma Shrivastav; Anuraag Shrivastav
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

5.  Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells.

Authors:  Marine Jacquier; Shiby Kuriakose; Apurva Bhardwaj; Yang Zhang; Anuraag Shrivastav; Stéphanie Portet; Shailly Varma Shrivastav
Journal:  Sci Rep       Date:  2018-08-28       Impact factor: 4.379

6.  Targeting N-myristoylation for therapy of B-cell lymphomas.

Authors:  Erwan Beauchamp; Megan C Yap; Aishwarya Iyer; Maneka A Perinpanayagam; Jay M Gamma; Krista M Vincent; Manikandan Lakshmanan; Anandhkumar Raju; Vinay Tergaonkar; Soo Yong Tan; Soon Thye Lim; Wei-Feng Dong; Lynne M Postovit; Kevin D Read; David W Gray; Paul G Wyatt; John R Mackey; Luc G Berthiaume
Journal:  Nat Commun       Date:  2020-10-22       Impact factor: 14.919

7.  N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating Ubiquitination of Targets.

Authors:  Guoqing Zhu; Feng Wang; Haojie Li; Xiao Zhang; Qi Wu; Ya Liu; Mingping Qian; Susu Guo; Yueyue Yang; Xiangfei Xue; Fenyong Sun; Yongxia Qiao; Qiuhui Pan
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.